Medicare Ends Special Payment Pathways for New FDA Breakthrough Devices

From October 2026, newly designated FDA breakthrough devices will no longer qualify automatically for supplementary inpatient and outpatient Medicare payments. CMS ended pathways that since 2020 had waived requirements to prove substantial clinical improvement or novelty.